Ildiko Lingvay

Sitert av

	Alle	Siden 2020
Sitater	30180	24891
h-indeks	64	58
i10-indeks	146	130

10000

5000

2500

7500

2010201120122013201420152016201720182019202020212022202320242025101 123 141 188 183 231 317 736 1155 1414 1958 2735 3612 5045 9096 1950

Offentlig tilgang

Vis alle

78 artikler

9 artikler

tilgjengelige

ikke tilgjengelige

Basert på finansieringsmandater

Medforfattere

Professor Melanie J DaviesDiabetes Research Centre, University of LeicesterVerifisert e-postadresse på uhl-tr.nhs.uk
Julio RosenstockDirector Dallas Diabetes Research CenterVerifisert e-postadresse på dallasdiabetes.com
Thomas WaddenUniversity of Pennsylvania, Department of PsychiatryVerifisert e-postadresse på pennmedicine.upenn.edu
Richard PratleyAdventHealth Translational Research InstituteVerifisert e-postadresse på adventhealth.com
Professor Tina Vilsbøll, MD DMScSteno Diabetes Center Copenhagen, University of Copenhagen, DenmarkVerifisert e-postadresse på regionh.dk
A. Michael LincoffProfessor of Medicine, Cleveland ClinicVerifisert e-postadresse på ccf.org
Juan FriasChief Medical Officer, Biomea FusionVerifisert e-postadresse på biomeafusion.com
Grazia AleppoProfessor of Medicine, Feinberg School of Medicine, Northwestern UniversityVerifisert e-postadresse på northwestern.edu
Kamlesh KhuntiProfessor of Primary Care Diabetes and Vascular Medicine, University of LeicesterVerifisert e-postadresse på le.ac.uk
John DeanfieldUniversity College LondonVerifisert e-postadresse på ucl.ac.uk
Anders Gaarsdal HolstAcesion Pharma and Department of Cardiology, University Hospital RigshospitaletVerifisert e-postadresse på kanten.dk
Ofri MosenzonProf. of Medicine, MD, MSc Regeneron Pharmaceuticals. Hebrew University of Jerusalem, IsraelVerifisert e-postadresse på regeneron.com
Lawrence LeiterUniversity of TorontoVerifisert e-postadresse på smh.ca
Sean WhartonAssistant Professor University of TorontoVerifisert e-postadresse på whartonmedicalclinic.com
Jorge Plutzky, MDBrigham and Women’s Hospital, Harvard Medical SchoVerifisert e-postadresse på bwh.harvard.edu
Donna H RyanProfessor Emerita, Pennington Biomedical Research CenterVerifisert e-postadresse på pbrc.edu
John B BuseUniversity of North CarolinaVerifisert e-postadresse på med.unc.edu
Mansoor HusainTed Rogers Centre for Heart Research, Toronto General Hospital Research Institute, U of TorontoVerifisert e-postadresse på uhn.ca
Steven P. MarsoHCA Mid AmericaVerifisert e-postadresse på hcahealthcare.com
Leigh PerreaultVerifisert e-postadresse på ucdenver.edu

Følg

Ildiko Lingvay

UT Southwestern Medical Center

Verifisert e-postadresse på utsouthwestern.edu

obesity diabetes cardiovascular disease NASH


Tittel Sorter etter sitater Sorter etter år Sorter etter tittel	Sitert av Sitert av	År
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ... New England Journal of Medicine 375 (19), 1834-1844, 2016	6136	2016
Once-weekly semaglutide in adults with overweight or obesity JPH Wilding, RL Batterham, S Calanna, M Davies, LF Van Gaal, I Lingvay, ... New England Journal of Medicine 384 (11), 989-1002, 2021	2976	2021
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ... New England Journal of Medicine 381 (9), 841-851, 2019	1692	2019
Semaglutide and cardiovascular outcomes in obesity without diabetes AM Lincoff, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, ... New England Journal of Medicine 389 (24), 2221-2232, 2023	1112	2023
Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial M Davies, L Færch, OK Jeppesen, A Pakseresht, SD Pedersen, ... The Lancet 397 (10278), 971-984, 2021	895	2021
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial D Rubino, N Abrahamsson, M Davies, D Hesse, FL Greenway, C Jensen, ... Jama 325 (14), 1414-1425, 2021	892	2021
9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes care 46 (Suppl 1), S140, 2022	856	2022
Cardiac Steatosis in Diabetes Mellitus: A ¹H-Magnetic Resonance Spectroscopy Study JM McGavock, I Lingvay, I Zib, T Tillery, N Salas, R Unger, BD Levine, ... Circulation 116 (10), 1170-1175, 2007	747	2007
Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical … TA Wadden, TS Bailey, LK Billings, M Davies, JP Frias, A Koroleva, ... Jama 325 (14), 1403-1413, 2021	741	2021
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial RE Pratley, VR Aroda, I Lingvay, J Lüdemann, C Andreassen, A Navarria, ... The lancet Diabetes & endocrinology 6 (4), 275-286, 2018	710	2018
Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial AJ Ahmann, M Capehorn, G Charpentier, F Dotta, E Henkel, I Lingvay, ... Diabetes care 41 (2), 258-266, 2018	560	2018
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension JPH Wilding, RL Batterham, M Davies, LF Van Gaal, K Kandler, K Konakli, ... Diabetes, Obesity and Metabolism 24 (8), 1553-1564, 2022	502	2022
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial R Pratley, A Amod, ST Hoff, T Kadowaki, I Lingvay, M Nauck, ... The Lancet 394 (10192), 39-50, 2019	499	2019
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation I Lingvay, P Sumithran, RV Cohen, CW le Roux The Lancet 399 (10322), 394-405, 2022	457	2022
Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial HW Rodbard, J Rosenstock, LH Canani, C Deerochanawong, ... Diabetes care 42 (12), 2272-2281, 2019	405	2019
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial HW Rodbard, I Lingvay, J Reed, R De La Rosa, L Rose, D Sugimoto, ... The Journal of Clinical Endocrinology & Metabolism 103 (6), 2291-2301, 2018	371	2018
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes Care 46 (Supplement_1), S68-S96, 2023	369	2023
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024 Diabetes Care 47 (Supplement_1), S158-S178, 2024	323	2024
Serum urate lowering with allopurinol and kidney function in type 1 diabetes A Doria, AT Galecki, C Spino, R Pop-Busui, DZ Cherney, I Lingvay, ... New England Journal of Medicine 382 (26), 2493-2503, 2020	322	2020
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5 RF Kushner, S Calanna, M Davies, D Dicker, WT Garvey, B Goldman, ... Obesity 28 (6), 1050-1061, 2020	291	2020

Systemet kan ikke utføre handlingen. Prøv på nytt senere.

Artikler 1–20

Sitater per år

Duplikatsitater

Sammenslåtte sitater

Legg til medforfattereMedforfattere

Følg

Sitert av

Medforfattere